Jason Meyenburg is the founder of Gemini Therapeutics. Gemini Therapeutics has raised $216M in total funding. Latest round: IPO.
Jason Meyenburg was the Chief Executive Officer of Gemini Therapeutics, a precision medicine company focused on age-related macular degeneration. The company went public on the Nasdaq Exchange in February 2021 through a merger with FS Development Corp., a SPAC sponsored by Foresite Capital.
Full founder directory · Investor directory · Company funding database · Fundraising library